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Abstract: Background: In the last years, several studies were conducted that evaluated biomarkers
that could be helpful for cardioembolic stroke diagnosis, prognosis, and the determination of risk of
stroke recurrence. Methods: We performed a narrative review of the main studies that evaluated
biomarkers related to specific cardioembolic causes: atrial fibrillation, patent foramen ovale, atrial
cardiomyopathy, and left ventricular wall motion abnormalities. Results: BNP and NT-proBNP are,
among all biomarkers of cardioembolic stroke, the ones that have the highest amount of evidence
for their use. NT-proBNP is currently used for the selection of patients that will be included in
clinical trials that aim to evaluate the use of anticoagulation in patients suspected of having a
cardioembolic stroke and for the selection of patients to undergo cardiac monitoring. NT-proBNP
has also been incorporated in tools used to predict the risk of stroke recurrence (ABC-stroke score).
Conclusions: NT-proBNP and BNP continue to be the biomarkers most widely studied in the context
of cardioembolic stroke. The possibility of using other biomarkers in clinical practice is still distant,
mainly because of the low methodological quality of the studies in which they were evaluated. Both
internal and external validation studies are rarely performed for most biomarkers.
Keywords: biomarker; cardioembolism; stroke; atrial fibrillation; patent foramen ovale; atrial car-
diomyopathy; NT-proBNP; BNP; ANP
1. Introduction
In many areas of medicine, biomarkers are currently used to help to diagnose, establish
prognoses, and to prescribe therapeutics to specific groups of patients that benefit the most
from differentiated treatments due to having particular phenotypes [1]. Moreover, in
neurology, several studies that evaluated biomarkers have been conducted in recent years,
namely in the area of stroke [2]. When compared to other medical areas, the application of
biomarkers to the field of cerebrovascular pathology has some obstacles: (a) the presence of
the blood–brain barrier that poses difficulties and delays the release of proteins of neuronal
or glial origin into the bloodstream after stroke; and (b) many of the potential serum
biomarkers of cerebral ischemia and inflammation have low specificity and may also be
increased in situations that can be confounded with stroke as they may present in a similar
way such as acute myocardial infarction or central nervous system inflammation [3].
Nevertheless, there could be clear benefits of the application of biomarkers in stroke.
Unravelling the cause of ischemic stroke can sometimes be challenging [4]. After an
extensive investigation about a third of ischemic stroke patients are classified as having
an undetermined stroke etiology [4]. It is possible that a fraction of these strokes that
are currently being classified as of undetermined etiology may indeed be cardioembolic.
Cardioembolic strokes are associated to a high morbidity and mortality [5] and some like
the ones associated to atrial fibrillation (AF) and to a patent foramen ovale (PFO) have
specific treatments that can reduce the risk of stroke recurrence.
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In this article, we aimed to perform a narrative review of the most recent literature
regarding biomarkers associated to cardioembolic stroke. We searched studies that evalu-
ated biomarkers associated to established cardioembolic etiologies like AF and PFO but
also associated to emerging new possible causes of cardioembolic stroke, such as atrial
cardiomyopathy and left ventricular wall motion abnormalities (LVWMA). We assessed
biomarkers associated to diagnosis, prognosis, and stroke risk and recurrence.
2. Atrial Fibrillation
Atrial fibrillation is one of the main causes of cardioembolic stroke. Strokes related to
AF are associated to a high morbidity and disability [5].
Current guidelines define presence of AF as electrocardiographic documentation of
absolutely irregular RR intervals and no discernible, distinct P waves lasting for at least
30 s. However, there is no evidence to suggest that a run of AF lasting > 30 s is more
important than several shorter episodes. On the other hand, our understanding of the
risk factors and complications of AF is based mostly on studies that have evaluated AF in
a binary fashion (present or absent) and have not investigated AF burden (quantity the
cumulative amount of AF that an individual has). It is unclear whether the risk increases
continuously or whether a threshold exists.
The diagnosis of paroxysmal AF may be challenging. To date, several studies explored
the use of prolonged noninvasive and invasive cardiac monitoring devices to identify AF.
Nevertheless, the current available methods to detect paroxysmal AF have low sensitivity.
It remains elusive which is the best method and the duration of monitoring to detect
paroxysmal AF. It is known that a 24-h ECG recording has a higher sensitivity for the
diagnosis of paroxysmal AF than a routine 12 lead ECG. In a systematic review [6] the
detection rate of paroxysmal AF by a 24–72 h ECG recording was of 4.6%. Due to the
low detection rate of this examination, there is some controversy regarding its clinical
utility and its routine use in the etiological investigation of ischemic stroke [7]. Serial ECG
assessments within the first 72 h of an acute stroke significantly improve detection of AF [8].
Automated analysis of continuous stroke unit ECG monitoring improves paroxysmal AF
detection in patients with stroke on stroke units compared with 24-h Holter ECG [9].
Randomized clinical trials like CRISTAL-AF [10] and EMBRACE [11] showed that
longer monitoring of the heart rhythm increased the probability of detecting atrial fibril-
lation in patients initially suspected of having a cryptogenic stroke (AF lasting > 30 s).
However, even in the CRISTAL-AF trial in which insertable cardiac monitors (ICM) were
used the rate of atrial fibrillation detection did not surpass 12.4% of patients in the ICM
group at 12 months [10].
A biomarker that could aid in the diagnosis of paroxysmal AF would be very helpful,
namely to select patients that could benefit the most from long term heart rhythm monitor-
ing. Several studies have analyzed possible biomarkers of AF. Most have analyzed levels
of biomarkers in patients with known AF. Only a few have prospectively analyzed how
biomarkers measured at baseline were predictive of AF.
2.1. NT-proBNP and BNP
2.1.1. Atrial Fibrillation Diagnosis
The majority of studies regarding possible biomarkers of AF in ischemic stroke refer to
the N-terminal of the pro-brain natriuretic peptide (NT-proBNP) and the brain natriuretic
peptide (BNP).
NT-proBNP is part of a group of natriuretic peptides, phylogenetically conserved
along time that includes peptides such as atrial natriuretic peptide (ANP), natriuretic
peptide type C, urodilatin and the Dendroaspis natriuretic peptide [12]. NT-proBNP is
coded by a gene composed by three exons and two introns that is located in chromosome
1p36.2. It is initially produced as a prepropeptide of 143 amino acids. This prepropeptide
is proteolytic cleaved into a non-active N-terminal fragment composed by 108 amino acids
designated proBNP. ProBNP after secretion is divided in two fractions by two proteolytic
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enzymes. These two fractions are BNP that is biological active (aa 77–108) and the N-
terminal-proBNP (NT-proBNP) (aa 1–76) without biological activity [13]. BNP and NT-
proBNP concentrations can be determined in blood samples [14]. The half-life of these two
peptides differs. NT-proBNP has a half-life superior to BNP. NT-proBNP has a half-life of
120 min and BNP a half-life of 22 min [15]. It is due to this difference in half-life that most
essays measure NT-proBNP instead of BNP. In the heart, BNP can be produced by both
atria and ventricles [16]. However, due to the larger ventricular mass, 70% of all BNP is
produced by the ventricle in normal conditions [17].
Higher levels of NT-proBNP and BNP have been consistently shown to be present
in patients with cardioembolic stroke associated to AF when compared to patients with a
noncardioembolic etiology [18,19]. In the first 72 h after ischemic stroke, NT-proBNP serum
levels have been shown to have a similar diagnostic accuracy to diagnose cardioembolic
stroke, although NT-proBNP levels were highest in the first two days after ischemic stroke
and declined significantly thereafter [20].
Several cut-off points for the diagnosis of cardioembolic stroke associated to AF
have been proposed. The use of different methodologies and assay kits may hamper
the establishment of a cut-off point that could be used in a generalized way. Although
NT-proBNP and BNP levels tend to increase with age and differ according to gender,
scarce studies searched for different cut-off points according to these characteristics [21].
Moreover, several conditions may increase NT-proBNP and BNP levels and be confounding
factors. Therefore, it is important to recognize what pathologies can be associated to
increased levels of natriuretic peptides. These include: acute ischemic heart disease, heart
failure, heart valve disease, renal failure, anemia, acute pulmonary embolism, pulmonary
hypertension, sepsis and hyperthyroidism [22]. Treatment with angiotensin-converting
enzyme inhibitors (ACEI), Angiotensin II receptor blockers (ARB), diuretics and Beta-
blockers can also increase NT-proBNP and BNP levels [22]. There is an inverse relationship
between natriuretic peptide levels and obesity (body mass index ≥ 30) [23].
Only some studies prospectively followed cryptogenic ischemic stroke patients to
determine if NT-proBNP levels measured at baseline at the time of ischemic stroke onset
could be predictors of a later diagnosis of AF [24]. In one study that analyzed serum levels
of NT-proBNP, eighty patients with cryptogenic stroke were followed during six months
to look for AF. In 17, paroxysmal AF was found during follow-up. In these patients, the
area under the curve for the diagnosis of paroxysmal AF was 0.83. The cut-off point of
265.5 pg/mL had a sensitivity of 88.2% and a specificity of 61.9%. The cutoff point of
912 pg/mL had a sensitivity of 47.1% and a specificity of 88.9% [24].
A systematic review with pooled meta-analysis that analysed NT-proBNP and BNP
reported that BNP/NT-proBNP levels were significantly elevated in cardioembolic stroke.
Predictive models showed a sensitivity >90% and specificity >80% when BNP/NT-proBNP
were added considering the lowest and the highest quartile, respectively. Both peptides also
significantly increased the area under the curve and integrated discrimination improvement
index compared with clinical models [25].
A clinical trial is currently using NT-proBNP concentrations levels to decide upon
further screening for AF [26]. The STROKESTOP II trial is a randomized, population-based
study of AF screening in individuals older than 75. All individuals with NT-proBNP >
125 ng/L and without known AF are taught to undergo intermittent ECG recordings twice
daily for two weeks (intervention group). Individuals with a NT-proBNP < 125 ng/L
do one initial 1-lead ECG, and if normal do not undergo further ECG screening (control
group). The primary outcome measure is the incidence of stroke or systemic embolism in
the control group versus the intervention group [26].
2.1.2. Stroke Recurrence
A study that used data from the ENGAGE AF-TIMI 48 which was a randomized trial
of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2,
evaluated NT-proBNP as a predictor of stroke recurrence in anticoagulated patients [27].
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This studied included 6308 patients. In a Cox regression model, upward changes in log2-
transformed NT-proBNP were associated with increased risk of stroke or systemic embolic
events in anticoagulated patients (adjusted hazard ratio (adj-HR) 1.74; 95% confidence
interval (CI) 1.36–2.23 and adj-HR 1.27; 95% CI 1.07–1.50, respectively) [27].
2.2. Atrial Natriuretic Peptide (ANP) and Midregional Fragment of the Precursor Hormone of
ANP (MR-proANP)
The Atrial natriuretic peptide (ANP) or atrial natriuretic factor (ANF) is a natriuretic
peptide hormone secreted from the atria. As it is only produced by the atria in contrast to
BNP and NT-proBNP that are both produced by atria and ventricles it could theoretically
be a biomarker more accurate to diagnose AF. MR-proANP is a stable fragment of the ANP
precursor hormone [28]. A retrospective study compared the diagnostic accuracy of ANP
and BNP. Two-hundred and twenty-two consecutive ischemic stroke patients within 48 h
after stroke onset were evaluated. Plasma ANP and BNP were simultaneously measured
at admission. One hundred and fifty-eight patients had no evidence of AF, 25 patients
had paroxysmal AF, and the other 39 patients had chronic AF. ANP was significantly
higher in the paroxysmal AF than in the sinus rhythm group (97 (50–157) mg/dL versus
42 (26–72) mg/dL, p < 0.05) and further increased in the chronic AF group (228 (120–392),
p < 0.05 versus paroxysmal AF and sinus rhythm groups). Similarly, the BNP value was
higher in the paroxysmal AF than in the sinus rhythm group (116 (70–238) mg/dL versus
34 (14–72) mg/dL, p < 0.05) and further increased in the chronic AF group (269 (199–423)
p < 0.05 versus paroxysmal AF and sinus rhythm groups). The area under the curve was
similar between ANP and BNP (0.76 and 0.80) [28].
In a prospective multicenter cohort study that quantified MR-proANP levels in is-
chemic stroke patients within 24 h of stroke onset, the diagnosis of AF at hospital discharge
were associated with MR-proANP with an OR of 18.35 (95% CI 7.94–42.45, p < 0.001) [29].
The continuous net reclassification index of MR-proANP for AF was 78%, 95% CI 60%–89%,
p < 0.001). MR-proANP levels ≥ 289 pmol/L had a specificity of 86% and sensitivity of
48% for the diagnosis of AF.
2.3. Interleukin-6
IL-6 is an inflammatory cytokine with pleiotropic effects on immune response and
inflammation. It is synthesized in immune cells such as macrophages and monocytes.
Emerging studies have proved that inflammation plays a key role in AF. Thrombogenesis
related to AF is also associated with inflammation [30].
A meta-analysis of five studies involving 22,928 patients showed that higher levels of
IL-6 in AF patients are related to the risk of long-term thromboembolic events including
stroke (RR 1.44, CI 95% 1.09–1.90, p = 0.01) [30]. A cut-off point of IL-6 needs to be defined.
2.4. Growth Differentiation Factor-15, Cystatin and High Sensitive Cardiac Troponin
A new biomarker-based risk score to improve the prognostication of major bleeding
in patients with AF was developed by Hijazi et al. [31]. The authors developed and
internally validated a new biomarker-based risk score for major bleeding in 14,537 patients
with AF randomized to apixaban versus warfarin in the ARISTOTLE trial and externally
validated it in 8468 patients with AF randomized to dabigatran versus warfarin in the
RE-LY trial. Plasma samples for determination of candidate biomarker concentrations
were obtained at randomization. The ABC-bleeding score, using age, history of bleeding,
and three biomarkers (hemoglobin, high sensitive cardiac troponin (cTn-hs), and growth
differentiation factor-15 (GDF-15) or cystatin C) was internally and externally validated
and calibrated in large cohorts of patients with AF receiving anticoagulation therapy. The
ABC-bleeding score performed better than the HAS-BLED and ORBIT scores [31]. GDF-15
is a marker of oxidative stress; cardiac troponin is linked to myocardial injury and cystatin
C is a marker of renal function.
An ABC-AF-stroke (age, biomarkers, prior stroke) has also been developed to improve
prognostication of stroke in patients with AF. This score incorporates NT-proBNP and
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cTn-hs levels as biomarkers, age and history of prior stroke/transient ischemic attack. It
was developed and internally validated in 14,701 patients with AF treated with oral antico-
agulation [32]. Biomarkers levels were evaluated at baseline and patients were followed for
a mean time of 1.9 years. An external validation was performed in 1400 patients with AF
with a median follow-up of 3.4 years. This score had a better accuracy to predict stroke in
patient with AF than the CHADS2DS2VASC score in the derivation and validation cohorts
(AUC of 0.68 vs. 0.62 p < 0.001 and 0.66 vs. 0.58 p < 0.001 respectively) [32].
Some studies have reported higher values at hospital admission of troponins (Cardiac
troponin I) in patients with cardioembolic stroke than in patients with non-cardioembolic
stroke. However, these studies did not discriminate the subtypes of cardioembolic stroke
that were included [33,34].
2.5. D-dimers
D-dimers are a breakdown product of fibrin. Baseline elevated d-dimers levels
(≥2 µg/mL) were found to be associated to a higher risk of recurrent ischemic stroke
in patients with AF with HR of 1.80 95% CI 1.13–2.84, p = 0.012 [35]. Some studies have
shown that elevated d-dimer levels are an independent predictor of the presence of left
atrial thrombus in patients with AF [36,37].
2.6. Genetics Biomarkers
RNAs present in the peripheral blood have been studied as potential biomarkers.
Changes in RNA expression in the blood of patients with cardioembolic stroke could reflect
inflammatory and prothrombotic changes specific to this stroke etiology [38]. Microarray
and RNA sequencing or PCR with reverse transcription allow the study of noncoding
and coding RNA transcripts. In a discovery-based study that collected blood samples
from 76 acute ischemic stroke patients, using whole genome microarrays, a 37-gene profile
was able to differentiate cardioembolic stroke due to AF from non-AF causes with >90%
sensitivity and specificity [38]. The identified genes reflected differences in inflammation
between stroke subtypes. The major source of RNA in the blood is immune cells including
leukocytes, neutrophils, and monocytes. This gene expression signature profile that was
identified needs to be validated in future, independent, larger studies [38].
MicroRNAs (miRNAs) are single-stranded, non-protein-coding RNAs composed of ap-
proximately 22 nucleotides [39]. They are involved in the regulation of post-transcriptional
gene expression by binding with the target mRNA at the 3′ untranslated region. Changes
in miRNA expression level are reported to be associated to different pathologies (39). The
modulation of miRNA expression has been reported to reduce or increase the susceptibility
to develop AF in vivo. This may be due to the regulation of atrial remodeling mechanisms
by miRNAs [39]. miRNAs could therefore not only be a biomarker but also a potential
therapeutic agent for the treatment of AF [40].
Treatment Implications
Biomarkers associated to the diagnosis of AF could be useful to select patients that
could benefit the most from long term heart monitoring. The ideal way to test this possible
application would be through a clinical trial, as is currently being tested in STROKESTOP
II [26].
The accuracy of established risk scores for stroke, such as the CHA2-DS2-VASc score
and the HAS-BLED could potentially be further improved by the addition of serum/
plasma biomarkers.
3. Patent Foramen Ovale
The foramen ovale is a flap-like communication between the right and the left atria
at the level of the fossa ovalis, which is present in the fetus and enables the venous blood
to bypass the non-functioning fetal lung and go directly to the left side of the heart [41].
The communication usually closes after birth however if the foramen persists after the
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age of one, it is called a patent foramen ovale (PFO). It can be found in up to 27% of
the general population [41]. Case–control studies demonstrated an association between
PFO and cryptogenic stroke (OR 2.9) especially in young adults (<55 years of age) [41,42].
In the last years, results of clinical trials reported a consistently higher benefit of PFO
closure compared to antiplatelet therapy in patients with an atrial septal aneurysm or large
right-to-left shunts [41]. Some studies were conducted to analyze how biomarkers may
help in the diagnosis of PFO or to predict the size of the right-to-left shunt or ischemic
stroke recurrence.
3.1. L-Arginine/Asymmetric Dimethylarginine Ratio
Sgarra et al. evaluated the correlation, in terms of severity, between the degree of
endothelial dysfunction assessed by the L-Arginine/asymmetric dimethylarginine ratio
(L-Arg/ADMA ratio), the methylene tetrahydrofolate reductase (MTHFR) genotype, and
the interatrial septum (IAS) phenotype in subject with a history of stroke [43]. L-arginine
is the substrate for NO generation and asymmetric dimethylarginine (ADMA), an en-
dogenous inhibitor of nitric oxide (NO) synthase. The study included 57 patients, and
10 had a septum integrum (SI), 38 a PFO, and nine an ostium secundum (OS). In the PFO
subgroup a negative correlation was found between the L-Arg/ADMA ratio and PFO
tunnel length/height ratio (p ≤ 0.05; r = −0.37; R2 = 0.14). The authors suggest that the
L-Arg/ADMA ratio could be used as a reliable marker of stroke susceptibility in carriers of
an interatrial septum abnormalities, hinting at its potential use both as a diagnostic tool
and as a decision aid for therapy [43].
3.2. Homocysteine
The 10-point risk of paradoxical embolism (RoPE) score is an index that was created to
stratify cryptogenic stroke patients with PFO by their likelihood that the stroke was related
to their PFO [44]. Zuin et al. found a direct correlation between serum homocysteine
levels and the RopE score in a sample of 244 PFO patients [45]. A receiver operating
curve identified the optimal cutoff value of 19.5 µg/dL for homocysteinemia as a predictor
of a high RoPE score > 7 in the group of patients with PFO that underwent a closure
procedure (AUC 0.90, 95% CI 0.81–0.94, p < 0.0001). Multivariate logistic regression
analysis demonstrated that a homocysteine serum level ≥ 19.5 µg/dL predicted a RoPE
score > 7 (OR 3.21, 95% CI 2.82–3.26, p < 0.0001) in closed patients independently from the
presence of a permanent right-to-left shunt (OR 2.28, 95% CI 2.01–2.43, p = 0.001) and atrial
septal aneurysm (OR 3.04, 95% CI 2.64–3.51, p < 0.0001) [45].
3.3. D-dimers
Kim et al. [46] followed 241 patients with PFO for a mean time of 34.0 ± 22.8 months.
During follow-up, all-cause death occurred in 58 (10.2%) patients, ischaemic stroke in
33 (5.8%), and pulmonary thromboembolism in 6 (1.1%). Multivariate Cox regression
analysis showed that a D-dimer level of >1000 ng/mL was an independent predictor for
recurrent ischaemic stroke in patients with PFO (hazard ratio 5.341, 95 % CI1.648–17.309,
p = 0.005), but not in those without a PFO.
Treatment Implications
None of the biomarkers that was reported in the studies analyzed was further vali-
dated. Therefore, none can be used in clinical practice.
4. Atrial Cardiomyopathy
4.1. Introduction
Atrial cardiomyopathy, as defined by a consensus expert group in 2016, consists of any
complex of structural, architectural, contractile or electrophysiological changes affecting
the atria with the potential to produce clinically-relevant manifestations [47]. This new
definition was a landmark and expanded the concept of cardioembolism, including primary
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atrial disorders as well as providing a framework for integrating the effects of diverse
upstream cardiac and systemic disorders that induce secondary atrial remodeling [48].
The actual prevalence of atrial cardiomyopathy is unknown but the extensive list
of associated predisposing factors, such as aging, high blood pressure, obesity, diabetes
mellitus, and obstructive sleep apnea, suggest that this is a frequently encountered and
important clinical condition [47,48]. Furthermore, there is growing evidence that supports
the role of atrial cardiomyopathy as an independent determinant of stroke risk, particularly
of embolic stroke subtypes [47,49–51]. Several biomarkers of left atrial dysfunction have
been proposed for the diagnosis of atrial cardiopathy, with most of the literature referring
to left atrial size (left atrial enlargement), P wave dispersion, P-wave terminal force in
lead V1 on EKG, paroxysmal supraventricular tachycardia, atrial high rate episodes, atrial
fibrosis, and elevation of serum biomarkers associated with atrial dysfunction like NT-
proBNP [52–54]. However, it should be noted that some of these biomarkers are not specific
to atrial dysfunction [52].
4.2. NT-proBNP
N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) has been shown to be associ-
ated with ischemic stroke, particularly cardioembolic stroke, independently of AF [55–57]
In a study that used the SPOTRIAS dataset, among 40 patients with cryptogenic
stroke, 63% had atrial cardiopathy as evidenced by the presence of at least one of the
biomarkers previously described. The most common finding was an elevation of NT-
proBNP > 250 pg/mL, present in 49% of cryptogenic stroke patients [58].
Although there is concurrent evidence that a NT-proBNP elevation is associated to
an increased likelihood of detecting paroxysmal AF in patients with ischemic stroke [59],
bearing in mind that with prolonged heart rhythm monitoring AF detection increases up
to 15–30% in cryptogenic stroke [10,11], that could imply that 19–34% of patients may have
an atrial cardiopathy without AF. The proportion of NT-proBNP elevation is probably not
solely explained by the effect that AF can have on NT-proBNP elevation, highlighting the
potential of NT-proBNP in atrial cardiopathy and cryptogenic stroke.
4.3. Genetics Biomarkers/Genetic Diseases Associated to Atrial Cardiomyopathy
Variants in genes that are functionally active in the cardiac atria and that contribute
to atrial development and/or maintenance of atrial electrical, structural, and metabolic
properties may directly cause or modify susceptibility to atrial cardiomyopathy [48].
However, the role of genetics in atrial cardiomyopathy is still in its infancy, and is
mostly useful in families with Mendelian forms of disease. For most people, the role of
genetics for the prediction of individualized risk of atrial cardiomyopathy and adverse
outcomes such as AF has yet to be established [48].
4.3.1. Natriuretic Peptide Precursor A Gene
The natriuretic Peptide Precursor A (NPPA) gene is responsible for the expression
of the atrial natriuretic peptide (ANP), an important molecule involved in atrial electric
remodelling prevention; intravascular blood volume and vascular tone regulation and ion
channel function regulation [60]. Fluctuations in ANP expression due to gene mutations
can disturb these mechanisms, contributing to atrial dysfunction. Indeed, atrial dilated
cardiomyopathy has been identified in patients with homozygous mutation in NPPA,
presenting with severely decreased levels of ANP and with clinical onset in adulthood of
biatrial dilatation, early supraventricular arrhythmias with progressive loss of atrial electric
activity to atrial standstill and secondary thromboembolic complications, while having a
stable normal left ventricular function and long-term stable functional class [46,61]. Patients
with this condition require pacemaker or cardioverter defibrillator implantation and chronic
anticoagulation because of the high prevalence of thromboembolic complications, most of
them consisting of cerebral embolic episodes [61].
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4.3.2. Myosin Light-Chain 4 Gene
Myosin light-chain 4 gene (MYL4) encodes the atrial-selective essential myosin light
chain. This essential myosin light chain is also known as atrial light chain 1, and is ex-
pressed in cardiac and skeletal muscle of the fetus and in the atria after birth, being a key
sarcomeric component and important atrial specific contractile protein [62,63]. Mutations
in MYL4 gene have been implicated in a primary atrial cardiomyopathy characterized by
atrial selective abnormalities associated with conduction system disease, stroke, and even-
tually mild ventricular dysfunction [62,63]. At least three kindreds have been described:
an Icelandic kindred presenting with atrial cardiomyopathy, with a frameshift mutation
in MYL4 associated with early-onset familial AF and bradyarrhythmias requiring pace-
maker insertion, ischaemic stroke and sudden death [62], a Canadian kindred presenting
with early-onset AF, conduction disease and reduced left atrial function as measured by
left atrial function index [64], and a Chinese kindred presenting with an inherited atrial
cardiomyopathy and atrial standstill as a prominent feature, evolving from contractile
abnormalities at a young age, followed by atrial arrhythmia, atrioventricular block, and
finally total atrial standstill [65].
Therapeutical Implications of Atrial Cardiomyopathy
Atrial cardiopathy can be an important cause of cryptogenic stroke and this emerg-
ing concept can have important therapeutical implications [66]. The evaluation of atrial
cardiopathy can identify patients with a thromboembolic prone left atrium, which could
lead to a cardioembolic stroke in the absence of AF [50,66,67]. Taking this into account,
anticoagulant therapies may well be of benefit for stroke prevention in a wider population
of patients than just those with AF. Preliminary evidence of this effect can be seen in an
analysis of the WARSS trial, in which a subgroup of patients with elevated NT-proBNP
had a substantially lower risk of recurrent stroke or death when treated with warfarin
rather than aspirin [57]. This result will be further elucidated trials such as the ARCADIA
and ATTICUS trial, which could prove the potential role of oral anticoagulation (apixaban
versus aspirin) for patients with cryptogenic stroke and atrial cardiopathy [66,67]. To be
included in the ARCADIA trial patients have to fulfill at least one of three criteria which
include a Serum NT-proBNP > 250 pg/mL (NT-proBNP criterion), P-wave terminal force >
5000 uv x ms in ECG lead V1, and left atrial diameter index ≥ 3 cm/m2. The ATTICUS
trial that will compare apixaban versus aspirin to prevent ischemic stroke recurrence does
not used serum biomarkers but electrocardiographic and echocardiogram parameters
suggestive of atrial cardiomyopathy to include patients namely one of the following: LA
size > 45 mm (parasternal axis), spontaneous echo contrast in the left atrial appendage
(LAA), LAA flow velocity ≤ 0.2 m/s, atrial high rate episodes, CHADSDS2-vass score ≥ 4,
FPO [67].
5. Left Ventricular Wall Motion Abnormalities
Left ventricular wall motion abnormalities (LVWMA) are a common finding detected
on echocardiographic evaluation of stroke patients. These changes are related with vari-
ous pathologies, such as coronary artery disease, congestive heart failure, stress-induced
cardiomyopathy, myocarditis or chronic renal disease [68]. It is believed that left ven-
tricular akinetic or hypokinetic segments could lead to a vulnerable environment where
thromboembolism may occur, induced by regional blood stasis and incomplete ventricular
emptying [66,69]. However, LVWMA role in stroke is still uncertain [67].
5.1. NT-proBNP
There is evidence relating NT-proBNP elevations and cardioembolic stroke [15,16].
However, its applicability for determining the presence of LVWMA is less well established.
Hosomi et al. studied the levels of BNP and particular left ventricle segment asynergy in
patients who had an ischaemic stroke and had a previous history of an old myocardial
infarction [70]. Patients with AF were excluded, and based on their results, cardioembolic
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stroke was associated with a high plasma BNP level, independently of a left ventricular
ejection fraction less than 40% [70]. High plasma BNP levels (>206.9 pg/mL) and left ven-
tricular wall motion abnormalities in the segments perfused by the left anterior descending
coronary artery or right coronary artery showed a high risk for cardioembolic stroke in
patients with old myocardial infarction.
5.2. Genetics
LVWMA can be found in patients with cardiac pathology, namely in familial car-
diomyopathies such as hypertrophic cardiomyopathy and dilated cardiomyopathy [71,72].
Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease
that is inherited in an autosomal dominant pattern in more than 90% of cases [73]. Over
1500 mutations in at least 15 sarcomere-encoding genes have been identified [74]. About
70% of these mutations are in the sarcomere genes encoding cardiac β-myosin heavy chain
(MYH7) and cardiac myosin binding protein C (MYBPC3) [73]. Mutations in troponin
T (TNNT2), troponin I (TNNI3), and α-tropomyosin (TPM1) are relatively uncommon
causes of HCM and together are responsible for less than 10% of cases [75,76]. Mutations in
cardiac α-actin A(CTC1), myosin light chain 2 (MYL2), myosin light chain 3 (MYL3), and
Cysteine and Glycine Rich Protein 3 (CSRP3) are other known rare causes of HCM [75].
Dilated cardiomyopathy (DCM) is a heart-muscle disorder characterized by systolic
dysfunction and dilatation of the left ventricle with normal left ventricular wall thick-
ness [77]. Familial genetic forms of DCM represent 20–40% of patients [77,78]. Up to
40 genes have been implied in DCM, inherited primarily in an autosomal dominant pat-
tern [77,79]. These genes encode for a wide variety of proteins of the sarcomere, cytoskele-
ton, nuclear envelope, sarcolemma, ion channels and intercellular junctions [77]. The most
common mutations involve sarcomere proteins, in particular titin (TTN) truncating muta-
tions, which are responsible for 25% of familial DCM [77]. Other sarcomere genes mutated
in DCM are MYH7 (encoding myosin 7, also known as β-myosin heavy chain), MYH6 (en-
coding myosin 6, also known as α-myosin heavy chain), MYBPC3 (encoding cardiac-type
myosin-binding protein C), TNNT2, TNNI3, TPM1, MYL2, MYL3 and ACTC1. The most
common gene mutated involving nuclear envelope is LMNA, encoding the intermediate
filament proteins lamins A and C and responsible for 8% of familial DCM [77–79].
Therapeutical Implications of Left Ventricular Wall Motion Abnormalities
Left ventricular wall motion abnormalities are an important finding in echocardio-
graphic study of ischaemic stroke patients and may be an independent predictor of stroke
recurrence [68,69]. Moreover, LVWMA can present as an echocardiographic finding due to
previous cardiac disease, namely myocardial infarction. Anterior apical MI is more likely
to result in LV thrombus formation and is associated with cerebral embolism [80]. The
detailed role of LVWMA could be assessed in trials evaluating direct oral anticoagulants
for prevention of stroke recurrence or systemic embolism in patients with embolic stroke
of undetermined source, especially in the analysis of subpopulations with LVWMA.
6. Conclusions
Several biomarkers related to cardioembolism are currently being studied (Table 1).
However, NT-proBNP and BNP are still the biomarkers that have been most studied
in the context of cardioembolic stroke and for which more evidence exists. Various studies
and meta-analysis evaluated these substances as biomarkers of cardioembolic stroke or
as predictors of AF. More recently, NT-proBNP and BNP have been used in clinical trials
for the selection of patients. These peptides also are starting to be incorporated in risk
prediction scores. The majorities of other substances that are currently being evaluated
as biomarkers related to cardioembolism, however, are far from being able to be used
in clinical trials. This is mainly due to the low methodological quality of most of these
studies. Frequently, only a small number of patients are included (<100 patients), and the
number of studies that have either an internal or external validation of the cut-off points is
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very low. Greater adherence to methodological criteria could help to translate results to
clinical practice.
Table 1. Summary of biomarkers related to cardioembolic sources and the application in which they are currently being
evaluated.
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